Zobrazeno 1 - 4
of 4
pro vyhledávání: '"G. Bortolus"'
Autor:
G. Pelizzari, L. Caggiari, M. Battiston, F. Cortiula, G. Targato, S. Buriolla, M. Bortolot, S. Torresan, M. Alberti, A. Michelotti, G. Bortolus, S. Urban, S. Pizzolitto, G. Fasola, A. Follador, G. De Maglio
Publikováno v:
Journal of Thoracic Oncology. 17:S510-S511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4d1a831162135fb4f589ecf6d997270
https://doi.org/10.1016/j.jtho.2022.07.901
https://doi.org/10.1016/j.jtho.2022.07.901
Autor:
Giovanni Frezza, O. Gabriele, S. Meregalli, A. Bonetta, G. Bortolus, Salvina Barra, Marco Signor, F. Mattana, Giuseppe Malinverni, Cinzia Iotti, G. Moro, Paolo Antognoni, F. Maurizi, Filippo Bertoni, A. Colombo
Publikováno v:
Radiotherapy and Oncology. :S354-S355
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca873a083429b4225d7d2fe3d6cebb5
Autor:
Salvatore Antonio Pignata, Luca Galli, Marcello Tucci, Giovanni Re, Andrea Sbrana, Cristina Masini, Pierpaolo Alongi, Stefano Fanti, Gaetano Facchini, Renato Costa, Sergio Baldari, Roberto Bortolus, Davide Donner, Enrico Cortesi, Eugenio Borsatti, Matteo Salgarello, Orazio Caffo, Alessandra Morabito, Carmine Pinto, Clizia Zichi, M. Spada, Giuseppe De Vincentis, Fabio Monari, Ugo De Giorgi, Filippo Alongi, Viviana Frantellizzi
Background: The retrospective studies that have so far described the outcomes of the sequential use of life-prolonging agents (LPAs) did not include metastatic castration-resistant prostate cancer (mCRPC) patients who received radium-223 (223Ra) as p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81065f78198a7f70a960a3b647e858c1
http://hdl.handle.net/11585/856175
http://hdl.handle.net/11585/856175
Autor:
Sergio Baldari, Elisa Biasco, Matteo Salgarello, Stefano Fanti, Orazio Caffo, Pierpaolo Alongi, Gaetano Facchini, Enrico Cortesi, Viviana Frantellizzi, Eugenio Borsatti, Giuseppe De Vincentis, Fabio Monari, Roberto Bortolus, Alessandra Murabito, Angelina Filice, Clizia Zichi, Renato Costa, Salvatore Antonio Pignata, Andrea Sbrana, Massimiliano Spada, Carmine Pinto, Filippo Alongi, Marcello Tucci, Antonio Palermo
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4f40ca1336d91555d8baa47a12b1ff
http://hdl.handle.net/11570/3193900
http://hdl.handle.net/11570/3193900